913377-45-4

Basic information

• Product Name: 2,2-diMethyl-5-((thiophen-3-ylaMino)Methylene)-1,3-dioxane-4,6-dione
• Synonyms: 2,2-diMethyl-5-((thiophen-3-ylaMino)Methylene)-1,3-dioxane-4,6-dione;2,2-diMethyl-5-{[(thiophen-3-yl)aMino]Methylidene}-1,3-dioxane-4,6-dione
• CAS NO: 913377-45-4
• Molecular Formula: C₁₁H₁₁NO₄S
• Molecular Weight: 253.27434
• Mol File: 913377-45-4.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2,2-diMethyl-5-((thiophen-3-ylaMino)Methylene)-1,3-dioxane-4,6-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 2,2-diMethyl-5-((thiophen-3-ylaMino)Methylene)-1,3-dioxane-4,6-dione(913377-45-4)
• EPA Substance Registry System: 2,2-diMethyl-5-((thiophen-3-ylaMino)Methylene)-1,3-dioxane-4,6-dione(913377-45-4)

Safety Data

• Hazardous Substances Data: 913377-45-4(Hazardous Substances Data)

Usage

General Description

2,2-dimethyl-5-((thiophen-3-ylamino)methylene)-1,3-dioxane-4,6-dione is a chemical compound with a complex molecular structure. It contains a dioxane ring with two methyl groups and a thiophen-3-ylamino group attached to it. 2,2-dimethyl-5-((thiophen-3-ylamino)methylene)-1,3-dioxane-4,6-dione is commonly used as an intermediate in the synthesis of other organic compounds, particularly in the pharmaceutical and agrochemical industries. It may also have potential applications in materials science and organic electronics due to its unique molecular structure. However, due to its complex nature and potential reactivity, proper handling and storage of this chemical are necessary to ensure safety in its use.

Upstream product

• 2033-24-1 cycl-isopropylidene malonate 
• 17721-06-1 3-aminothiophene 
• 122-51-0 orthoformic acid triethyl ester 
• 149-73-5 trimethyl orthoformate 
• 861965-63-1 thiophen‐3‐amine oxalate 

Downstream Products

• 69627-02-7 thieno[3,2-b]pyridin-7(4H)-one 
• 69627-03-8 7-chlorothieno[3,2-b]pyridine 
• 1228102-89-3 2-bromo-N-(3-(4-methoxybenzyloxy)phenyl)thieno[3,2-b]pyridin-7-amine 
• 1228102-90-6 4-(7-(3-(4-methoxybenzyloxy)phenylamino)thieno[3,2-b]pyridin-2-yl)benzaldehyde 
• 1228102-91-7 3-(7-(3-(4-methoxybenzyloxy)phenylamino)thieno[3,2-b]pyridin-2-yl)benzaldehyde 
• 1228103-34-1 N-(3-(4-methoxybenzyloxy)phenyl)-2-(4-(piperidin-1-ylmethyl)phenyl)thieno[3,2-b]pyridin-7-amine 
• 1228102-50-8 3-(2-(4-(piperidin-1-ylmethyl)phenyl)thieno[3,2-b]pyridin-7-ylamino)phenol trifluoroacetic acid 
• 1228103-41-0 N-(3-(4-methoxybenzyloxy)phenyl)-2-(3-(piperidin-1-ylmethyl)phenyl)thieno[3,2-b]pyridin-7-amine 
• 871690-72-1 3-fluoro-4-(thieno[3,2-b]pyridin-7-yloxy)aniline 
• 225382-63-8 [2-(3-Methyl-3H-imidazol-4-yl)-thieno[3,2-b]pyridin-7-yl]-(2-methyl-1H-indol-5-yl)-amine 
• 69627-02-7 thieno[3,2-b]pyridin-7-ol 

Relevant articles and documents

Design, synthesis and biological evaluation of novel N-sulfonylamidine-based derivatives as c-Met inhibitors via Cu-catalyzed three-component reaction

In our continuing efforts to develop novel c-Met inhibitors as potential anticancer candidates, a series of new N-sulfonylamidine derivatives were designed, synthesized via Cu-catalyzed multicomponent reaction (MCR) as the key step, and evaluated for their in vitro biological activities against c-Met kinase and four cancer cell lines (A549, HT-29, MKN-45 and MDA-MB-231). Most of the target compounds showed moderate to significant potency at both the enzyme-based and cell-based assay and possessed selectivity for A549 and HT-29 cancer cell lines. The preliminary SAR studies demonstrated that compound 26af (c-Met IC50 = 2.89 nM) was the most promising compound compared with the positive foretinib, which exhibited the remarkable antiproliferative activities, with IC50 values ranging from 0.28 to 0.72 μM. Mechanistic studies of 26af showed the anticancer activity was closely related to the blocking phosphorylation of c-Met, leading to cell cycle arresting at G2/M phase and apoptosis of A549 cells by a concentration-dependent manner. The promising compound 26af was further identified as a relatively selective inhibitor of c-Met kinase, which also possessed an acceptable safety profile and favorable pharmacokinetic properties in BALB/c mouse. The favorable drug-likeness of 26af suggested that N-sulfonylamidines may be used as a promising scaffold for antitumor drug development. Additionally, the docking study and molecular dynamics simulations of 26af revealed a common mode of interaction with the binding site of c-Met. These positive results indicated that compound 26af is a potential anti-cancer candidate for clinical trials, and deserves further development as a selective c-Met inhibitor.

ANTI-INFLAMMATORY COMPOUND HAVING INHIBITORY ACTIVITY AGAINST MULTIPLE TYROSINE KINASES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

The present invention is for the anti-inflammatory compounds that have an inhibitory activity against protein tyrosine kinases and their pharmaceutical composition(s) containing the compound as the active ingredient. Since the compounds of the present invention can inhibit multiple protein kinases associated with inflammatory diseases and immune disorders, they are useful for their prevention or treatment.